Covington, KY. Bexion Pharmaceuticals was one of 17 companies selected for a Podium Presentation at the NCI’s Small Business Innovation Research (SBIR) Venture Forum held on November 19, 2014 in Cupertino, California. Dr. Ray Takigiku, CEO and Co-Founder of Bexion delivered a scientific and financial overview of Bexion to an audience of top pharma and biotech executives and venture capital managers seeking the most promising potential partnerships.
Featured companies were recommended to present at this Forum through a competitive review process by an independent panel of investors and strategic partners including, but not limited to Janssen, Merck, Pfizer, Celgene, Varian, GE Ventures, BD Biosciences, DFJ Mercury and others. These 28 SBIR-funded companies (17 podium presenters and 11 poster presenters) represented promising innovators developing the next generation of cancer, therapeutics, diagnostics, and devices primed for commercialization.
“Bexion was honored to be included in such an impressive group of companies,” stated Dr. Takigiku. “We’ve had the privilege of having support from the NCI since our earliest days, and are now excited by the discussions with potential partners that were initiated at this event.”